VRAX (Virax Biolabs Group) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
44 GF Score
Price $3.89
GF Value $3.63
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

VRAX
44GF Score
Virax Biolabs Group Ltd VRAX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.89 is trading 7.2% above its estimated GF Value™ of $3.63. GuruFocus considers Virax Biolabs Group to be Fairly Valued.

Key valuation signals for VRAX:

  • Dividends Received:
  • GF Value™: $3.63 vs. price of $3.89 (7.2% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score

Get the complete analysis for VRAX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.89
Price
$3.63
GF Value